Insurers and PBMs are increasingly implementing white-bagging policies, which require oncology practices to obtain physician-administered infusions and other medications from designated specialty pharmacies often owned by or affiliated with insurers and their PBMs.
Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized. With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business.
Experts agree there are some concrete steps healthcare providers can take to ensure AI will be integrated more smoothly and equitably. Some of these measures include ensuring that models are trained on diverse datasets, keeping clinicians in the loop and prioritizing patient consent.
Many digital health startups aren't built with Medicaid members in mind. That's why Health Net created a request for information process to help the insurer determine which startups are the best fit for its Medicaid population, according to Dr. Pooja Mittal, vice president and chief health equity officer at Health Net.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling activating certain pathways but not others is key to setting its drugs apart from others in the same class.